The license agreement is expected to enable Aragen Bioscience to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient and stable production of preclinical and clinical grade material.
The collaboration of Cevec’s novel and proprietary Cap and Cap-T expression systems and cell lines with Aragen Bioscience’s experience in cell line and process development is expected to provide biotechnology and biopharmaceutical companies the opportunity to utilise Aragen’s services to gain access to Cevec’s technology and obtain pre-clinical and clinical grade product generated from stable as well as transiently transfected cell lines.
The transient Cap-T protein production technology is based on Cap cells, an immortalised cell line for stable protein production developed by Cevec. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.
Wolfgang Kintzel, CCO of Cevec, said: “Our human amniocyte derived cells offer advantages when it comes to complex protein production and we are excited that Aragen has chosen our technology as a valuable addition to their existing service offerings.“
Rick Srigley, CEO of Aragen Bioscience said: “We are very excited about the potential of Cevec’s Cap and Cap-T technology. Cevec’s technology is a valuable addition to our existing expression portfolio and is expected to enable our customers to pursue new directions for proteins that were difficult to express in the past or did not show satisfactory posttranslational modifications.”